First in Israel: New Technology for Treating Atrial Fibrillation

Two patients at Laniado Hospital in Netanya underwent the first treatment in Israel using Abbott's Volt PFA technology, which employs a balloon catheter with electrical pulses to treat atrial fibrillation without heat or cold. In a clinical study, over 84% of patients experienced no recurrence for a year. The procedures were completed successfully, but follow-up is required.

Two patients at Laniado Hospital in Netanya underwent the first treatment in Israel using Abbott's Volt PFA technology, which uses a balloon catheter with electrical pulses to treat atrial fibrillation without heat or cold. The patients suffer from complex underlying conditions, including diabetes and hypertension. The procedures were completed successfully, and pulmonary vein isolation was confirmed using a mapping system. In a clinical study published in June 2026, over 84% of patients experienced no documented recurrence for a year. However, the study did not include a control group, so the catheter has not been proven superior to existing ones. The potential advantage is reduced damage to surrounding tissues, but complications such as cardiac tamponade have also been reported. The technology was approved by the FDA in December 2025.